Jun 10, 2025
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ADCElerate1 trial will enroll patients in the US and Europe Copenhagen,...
Apr 1, 2025
Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran RoyBaynes M.D., Ph.D. appointed as independent, non-executive Director Fang Z. Ni, Pharm.D. named Chief Financial Officer Company expands global footprint by establishing U.S....
Oct 29, 2024
Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announces that its CEO, Michael Pehl will join fellow...
Oct 8, 2024
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple STS subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety,...
Apr 4, 2024
Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma...